文献速递中枢神经肿瘤放疗放疗物理与技术

立体定向放射外科再程治疗脑转移瘤局部或边缘复发:局部控制与放射性坏死预测因素

Reirradiation With Stereotactic Radiosurgery After Local or Marginal Recurrence of Brain Metastases From Previous Radiosurgery.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-10-10

该多中心回顾性研究纳入102例活检证实的非小细胞肺癌脑转移患者共123个病灶,既往接受过SRS后出现局部或边缘复发并接受再程SRS(SRS2)。SRS2后1年和2年局部控制率分别为79%和72%,肿瘤体积≤1 cm3者局部控制更优;放射性坏死(RN)发生率20%,症状性RN(SRN)7%,SRS1和SRS2最大剂量≥40 Gy或SRS2 V12Gy>9 cm3与SRN风险升高相关。

要点

  • SRS2后1年和2年局部控制率分别为79%和72%。
  • 肿瘤体积≤1 cm3者局部控制更优(P<.005)。
  • SRS1和SRS2最大剂量≥40 Gy或SRS2 V12Gy>9 cm3与SRN风险升高相关。

核心结论

  • 再程SRS可获得较高的局部肿瘤控制率和较低的症状性放射性坏死率。
  • SRS2时V12Gy≤9 cm3且最大剂量<40 Gy可能降低放射性坏死和症状性放射性坏死的风险。

研究设计与样本

  • 多中心回顾性研究,纳入8家机构102例活检证实的非小细胞肺癌患者共123个经SRS治疗的脑转移病灶。
  • SRS2于2015至2020年实施,要求处方等剂量线与SRS1重叠,排除术前SRS患者。

主要发现

  • SRS2中位时间为SRS1后12个月。
  • SRS2中位边缘剂量18 Gy(IQR 16-18)至50%(IQR 50%-70%)等剂量线,最大剂量30.5 Gy(IQR 25.0-36.0),V12Gy为3.38 cm3(IQR 0.83-7.64)。
  • 1年和2年局部控制率分别为79%和72%。
  • 肿瘤体积≤1 cm3者局部控制改善(P<.005)。
  • 放射性坏死25例(20%),症状性放射性坏死9例(7%)。

关键数值与推荐

  • SRS1和SRS2最大剂量≥40 Gy或SRS2 V12Gy>9 cm3时症状性放射性坏死率更高(各自P<.025)。
  • SRS1和SRS2最大剂量≥40 Gy也预测放射性坏死增加(各自P<.05)。
  • 既往免疫治疗不预测放射性坏死或症状性放射性坏死。

临床怎么用

  • 对于SRS后局部或边缘复发的脑转移瘤,可考虑再程SRS,尤其适用于体积约1 cm3且间隔约1年的病灶。
  • SRS2计划时应尽量将V12Gy控制在≤9 cm3且最大剂量<40 Gy以降低放射性坏死风险。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Brain metastases represent a major indication for stereotactic radiosurgery (SRS), but further study is needed regarding repeat SRS (SRS2) after local or marginal recurrence after prior SRS (SRS1). We report local tumor control (LC) after SRS2 and identify predictors of radiation necrosis (RN) and symptomatic RN (SRN). METHODS AND MATERIALS: Patients had biopsy-proven non-small cell lung cancer and at least 1 brain metastasis previously treated with SRS. SRS2 was performed from 2015 to 2020 and required overlap of the prescription isodose lines with those from SRS1. Patients treated with preoperative SRS were excluded. Primary endpoints were LC by Response Assessment in Neuro-oncology criteria, RN, and SRN. RESULTS: From 8 institutions, 102 patients with 123 treated lesions were included. SRS2 was performed at a median 12 months after SRS1. SRS2 delivered a median 18 Gy (interquartile range [IQR], 16-18) margin dose to the 50% (IQR, 50%-70%) isodose line, maximum dose of 30.5 Gy (IQR, 25.0-36.0), and V12Gy of 3.38 cm3 (IQR, 0.83-7.64). One-year and 2-year LC were 79% and 72%, respectively. Local tumor control was improved with tumor volume ≤1 cm3 (P < .005). There were 25 (20%) cases of RN and 9 (7%) cases of SRN. For SRS1 and SRS2, SRN rates were higher with maximum doses ≥40 Gy or SRS2 V12Gy >9 cm3 (P < .025 for each). SRS1 and SRS2 maximum dose ≥40 Gy was also predictive of increased RN (P < .05 for each). Prior immunotherapy was not predictive of RN or SRN. CONCLUSIONS: Repeat SRS afforded a high rate of local tumor control and a low rate of SRN. At SRS2, V12Gy ≤9 cm3 and maximum dose <40 Gy may reduce the risks of RN and SRN. These results are most applicable to lesions with approximately 1 cm3 volume and 1-year interval between SRS courses.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kowalchuk RO, Niranjan A, Lee CC, et al. Reirradiation With Stereotactic Radiosurgery After Local or Marginal Recurrence of Brain Metastases From Previous Radiosurgery. Int J Radiat Oncol Biol Phys. 2021. PMID: 34644606. doi:10.1016/j.ijrobp.2021.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。